Skip to main content
Premium Trial:

Request an Annual Quote

European Sales Lead Beckman Coulter to Post 10 Percent Jump in Q4 Revenue

NEW YORK, Jan. 28 - Beckman Coulter on Monday reported that fourth-quarter earnings swelled more than 12 percent to $48.3 million, or 75 cents per share, nudged by robust sales growth of its robotic genetic analysis tools. 

The company added that a greater than 16 percent rise in European sales helped increase total revenue by 10 percent to $578.3 million from $525.3 million in the year-ago period.

Sales in the quarter ended Dec. 31 were driven by a 13.2 percent increase in the company's immunodiagnostics products, which reached $107.2 million, and a 34.5 percent climb in robotic genetic analysis product sales, which generated $60 million.

Beckman Coulter predicts that 2002 will see sales rising 7 percent to 8 percent, and earnings growing 18 percent to 20 percent. So far this fiscal first quarter, the company estimates an earnings increase of roughly 20 percent, with sales up by approximately 7 percent.

The Fullerton, Calif.-based firm also said that it will report sales from three categories beginning in the first quarter. The categories will be clinical diagnostics, life-science research, and specialty testing.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.